Regadenoson

CAS 313348-27-5 11 current records 1 historicalSmall Molecule

Who holds supplier records for Regadenoson? 11 organisations hold a current record for Regadenoson: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (6), Taiwan (1) and Switzerland (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Regadenoson: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/regadenoson

Reading the evidence

  • 11 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    6 of the 8 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Regadenoson expires 2 Feb 2027. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (11)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Regadenoson. Country is the organisation's recorded country, not necessarily the manufacturing site.

India6Taiwan1Switzerland1Country not recorded for 3
  • GLAND PHARMA LTD
    Active DMF 27972, 37226 · latest filing Jun 2022
    India Company GMP cert on record
  • BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED
    Active DMF 30834 · latest filing Sept 2016
    India
  • CURIA MISSOURI INC
    Active DMF 30542 · latest filing May 2016
  • CZECH-GEN AS
    Active DMF 35433 · latest filing Jan 2021
    Company GMP cert on record
  • MATRIX PHARMACORP PRIVATE LTD
    Active DMF 32339 · latest filing Jan 2018
    India
  • MSN LIFE SCIENCES PRIVATE LIMITED
    Active DMF 36338 · latest filing Nov 2021
    India Company GMP cert on record
  • NANJING HERON PHARMACEUTICAL CO LTD
    Active DMF 36679 · latest filing Jan 2022
  • SCINOPHARM TAIWAN LTD
    Active DMF 28939 · latest filing Dec 2014
    Taiwan
  • Sun Pharmaceutical Industries Limited
    Active DMF 31539 · latest filing Nov 2017
    India Company GMP cert on record
  • USV PRIVATE LTD
    Active DMF 29315 · latest filing Jun 2015
    India Company GMP cert on record
  • WOCKHARDT BIO AG
    Active DMF 29185 · latest filing Mar 2015
    Switzerland
Need Regadenoson sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Regadenoson are no longer active. These show a past filing, not current supply.

Show all 1 historical record

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (12 listed products contain Regadenoson). The latest listed patent expires 2 Feb 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Regadenoson is a selective A2A adenosine receptor agonist used as a pharmacologic stress agent for myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It is used clinically to help diagnose coronary artery disease via its ability to increase blood flow in the coronary vasculature.

Chemical identity

IUPAC name
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide;hydrate
Canonical SMILES
CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N.O
InChIKey
CDQVVPUXSPZONN-WPPLYIOHSA-N
Synonyms
Lexiscan API, cvt-3146, lexiscan, rapiscan, regadenoson hydrate, regadenoson monohydrate

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Pharmacologic Cardiac Stress Test Agent
Mechanism of action
Adenosine Receptor Agonists

Therapeutic areas

CardiologyRadiologyDiagnostic Imaging

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Regadenoson?

11 organisations hold an active US FDA Type II Drug Master File or a CEP for Regadenoson: GLAND PHARMA LTD (India), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CURIA MISSOURI INC, CZECH-GEN AS, MATRIX PHARMACORP PRIVATE LTD (India), MSN LIFE SCIENCES PRIVATE LIMITED (India), NANJING HERON PHARMACEUTICAL CO LTD and SCINOPHARM TAIWAN LTD (Taiwan), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Regadenoson Drug Master Files are active?

GLAND PHARMA LTD (DMF 27972, 37226), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 30834), CURIA MISSOURI INC (DMF 30542), CZECH-GEN AS (DMF 35433), MATRIX PHARMACORP PRIVATE LTD (DMF 32339), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 36338), NANJING HERON PHARMACEUTICAL CO LTD (DMF 36679) and SCINOPHARM TAIWAN LTD (DMF 28939) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Regadenoson records mean?

1 organisation has only inactive Type II DMFs for Regadenoson. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Regadenoson?

Yes. The latest patent listed for an approved US product containing Regadenoson expires 2 Feb 2027, across 12 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Regadenoson supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Regadenoson?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.